Antisense Therapeutics company info

What does Antisense Therapeutics do?
Antisense Therapeutics (ASX:ANP) is an Australian biotechnology company developing and commercialising antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc (NASDAQ:IONS), an established leader in antisense drug development. Antisense's flagship product is ATL1102, an antisense drug for the treatment of Duchenne muscular dystrophy (DMD). ATL1102 is currently in Phase 2b clinical trials, and it has the potential to be the first approved treatment for DMD. Antisense is also developing other antisense drugs for the treatment of rare diseases, including acromegaly, limb-girdle muscular dystrophy, and long COVID.
Antisense Therapeutics company media
Company Snapshot

Is Antisense Therapeutics a public or private company?

key
Ownership
Public

How many people does Antisense Therapeutics employ?

people
Employees
10

What sector is Antisense Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Antisense Therapeutics?

location pin
Head Office
Victoria, Australia

What year was Antisense Therapeutics founded?

founded flag
Year Founded
2000
What does Antisense Therapeutics specialise in?
/Biotech /Pharmaceutical /Health /Medtech /Therapeutics

What are the products and/or services of Antisense Therapeutics?

Overview of Antisense Therapeutics offerings
ATL1102 for DMD: ATL1102 is a first-in-class antisense drug that has the potential to be the first approved treatment for DMD.
ATL1102 for long COVID: Antisense is investigating the potential of ATL1102 to treat long COVID, a post-COVID-19 condition that can cause a variety of symptoms, including fatigue, shortness of breath, and cognitive impairment.
ATL1102 for the treatment of Multiple Sclerosis.
ATL1103 for acromegaly: ATL1103 is an antisense drug in Phase 1 clinical trials for the treatment of acromegaly, a rare hormonal disorder that causes excessive growth.
Other projects: Antisense is also developing antisense drugs for the treatment of limb-girdle muscular dystrophy and other rare diseases.

Who is in the executive team of Antisense Therapeutics?

Antisense Therapeutics leadership team
  • Dr. James  Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA
    Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA
    CEO, MD & Director
  • Dr. Anthony  Filippis
    Dr. Anthony Filippis
    Chief Operating Officer
  • Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A.
    Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A.
    CFO & Joint Company Secretary
  • Ms. Alicia  Mellors
    Ms. Alicia Mellors
    Joint Company Secretary